These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 25155387)

  • 21. Hepatitis C virus NS3-4A serine protease inhibitors: use of a P2-P1 cyclopropyl alanine combination for improved potency.
    Bogen S; Saksena AK; Arasappan A; Gu H; Njoroge FG; Girijavallabhan V; Pichardo J; Butkiewicz N; Prongay A; Madison V
    Bioorg Med Chem Lett; 2005 Oct; 15(20):4515-9. PubMed ID: 16112862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Depeptidization efforts on P3-P2' alpha-ketoamide inhibitors of HCV NS3-4A serine protease: effect on HCV replicon activity.
    Bogen SL; Ruan S; Liu R; Agrawal S; Pichardo J; Prongay A; Baroudy B; Saksena AK; Girijavallabhan V; Njoroge FG
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1621-7. PubMed ID: 16387495
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis C virus NS3-4A serine protease inhibitors: SAR of new P1 derivatives of SCH 503034.
    Bogen S; Arasappan A; Pan W; Ruan S; Padilla A; Saksena AK; Girijavallabhan V; Njoroge FG
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4219-23. PubMed ID: 18547808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibitors of hepatitis C virus NS3/4A: alpha-ketoamide based macrocyclic inhibitors.
    Avolio S; Robertson K; Hernando JI; DiMuzio J; Summa V
    Bioorg Med Chem Lett; 2009 Apr; 19(8):2295-8. PubMed ID: 19285390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel inhibitors of hepatitis C NS3-NS4A serine protease derived from 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid.
    Venkatraman S; Njoroge FG; Wu W; Girijavallabhan V; Prongay AJ; Butkiewicz N; Pichardo J
    Bioorg Med Chem Lett; 2006 Mar; 16(6):1628-32. PubMed ID: 16413182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitors of hepatitis C virus NS3.4A protease: an overdue line of therapy.
    Perni RB; Kwong AD
    Prog Med Chem; 2002; 39():215-55. PubMed ID: 12536674
    [No Abstract]   [Full Text] [Related]  

  • 27. Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor.
    McCauley JA; McIntyre CJ; Rudd MT; Nguyen KT; Romano JJ; Butcher JW; Gilbert KF; Bush KJ; Holloway MK; Swestock J; Wan BL; Carroll SS; DiMuzio JM; Graham DJ; Ludmerer SW; Mao SS; Stahlhut MW; Fandozzi CM; Trainor N; Olsen DB; Vacca JP; Liverton NJ
    J Med Chem; 2010 Mar; 53(6):2443-63. PubMed ID: 20163176
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prime site binding inhibitors of a serine protease: NS3/4A of hepatitis C virus.
    Ingallinella P; Fattori D; Altamura S; Steinkühler C; Koch U; Cicero D; Bazzo R; Cortese R; Bianchi E; Pessi A
    Biochemistry; 2002 Apr; 41(17):5483-92. PubMed ID: 11969409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Solid-phase synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors.
    Sutton JC; Bolton SA; Davis ME; Hartl KS; Jacobson B; Mathur A; Ogletree ML; Slusarchyk WA; Zahler R; Seiler SM; Bisacchi GS
    Bioorg Med Chem Lett; 2004 May; 14(9):2233-9. PubMed ID: 15081015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and antiviral activity of novel HCV NS3 protease inhibitors with P4 capping groups.
    Li X; Liu Y; Zhang YK; Plattner JJ; Baker SJ; Bu W; Liu L; Zhou Y; Ding CZ; Zhang S; Kazmierski WM; Hamatake R; Duan M; Wright LL; Smith GK; Jarvest RL; Ji JJ; Cooper JP; Tallant MD; Crosby RM; Creech K; Wang A
    Bioorg Med Chem Lett; 2012 Dec; 22(24):7351-6. PubMed ID: 23142614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The design and synthesis of potent inhibitors of hepatitis C virus NS3-4A proteinase.
    Attwood MR; Bennett JM; Campbell AD; Canning GG; Carr MG; Conway E; Dunsdon RM; Greening JR; Jones PS; Kay PB; Handa BK; Hurst DN; Jennings NS; Jordan S; Keech E; O'Brien MA; Overton HA; King-Underwood J; Raynham TM; Stenson KP; Wilkinson CS; Wilkinson TC; Wilson FX
    Antivir Chem Chemother; 1999 Sep; 10(5):259-73. PubMed ID: 10574181
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and synthesis of ethyl pyrrolidine-5,5-trans-lactams as inhibitors of hepatitis C virus NS3/4A protease.
    Slater MJ; Andrews DM; Baker G; Bethell SS; Carey S; Chaignot H; Clarke B; Coomber B; Ellis M; Good A; Gray N; Hardy G; Jones P; Mills G; Robinson E
    Bioorg Med Chem Lett; 2002 Dec; 12(23):3359-62. PubMed ID: 12419361
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.
    Venkatraman S; Njoroge FG; Girijavallabhan VM; Madison VS; Yao NH; Prongay AJ; Butkiewicz N; Pichardo J
    J Med Chem; 2005 Aug; 48(16):5088-91. PubMed ID: 16078825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Structure-activity relationship studies of a bisbenzimidazole-based, Zn(2+)-dependent inhibitor of HCV NS3 serine protease.
    Yeung KS; Meanwell NA; Qiu Z; Hernandez D; Zhang S; McPhee F; Weinheimer S; Clark JM; Janc JW
    Bioorg Med Chem Lett; 2001 Sep; 11(17):2355-9. PubMed ID: 11527730
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis, and evaluation of oxygen-containing macrocyclic peptidomimetics as inhibitors of HCV NS3 protease.
    Velázquez F; Venkatraman S; Blackman M; Pinto P; Bogen S; Sannigrahi M; Chen K; Pichardo J; Hart A; Tong X; Girijavallabhan V; Njoroge FG
    J Med Chem; 2009 Feb; 52(3):700-8. PubMed ID: 19154150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Solid phase synthesis of aminoboronic acids: potent inhibitors of the hepatitis C virus NS3 proteinase.
    Dunsdon RM; Greening JR; Jones PS; Jordan S; Wilson FX
    Bioorg Med Chem Lett; 2000 Jul; 10(14):1577-9. PubMed ID: 10915055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors.
    Llinàs-Brunet M; Bailey M; Fazal G; Ghiro E; Gorys V; Goulet S; Halmos T; Maurice R; Poirier M; Poupart MA; Rancourt J; Thibeault D; Wernic D; Lamarre D
    Bioorg Med Chem Lett; 2000 Oct; 10(20):2267-70. PubMed ID: 11055335
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis C virus NS3 protease inhibitors comprising a novel aromatic P1 moiety.
    Rönn R; Lampa A; Peterson SD; Gossas T; Akerblom E; Danielson UH; Karlén A; Sandström A
    Bioorg Med Chem; 2008 Mar; 16(6):2955-67. PubMed ID: 18194867
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization.
    Prongay AJ; Guo Z; Yao N; Pichardo J; Fischmann T; Strickland C; Myers J; Weber PC; Beyer BM; Ingram R; Hong Z; Prosise WW; Ramanathan L; Taremi SS; Yarosh-Tomaine T; Zhang R; Senior M; Yang RS; Malcolm B; Arasappan A; Bennett F; Bogen SL; Chen K; Jao E; Liu YT; Lovey RG; Saksena AK; Venkatraman S; Girijavallabhan V; Njoroge FG; Madison V
    J Med Chem; 2007 May; 50(10):2310-8. PubMed ID: 17444623
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enzymatic characterization of membrane-associated hepatitis C virus NS3-4A heterocomplex serine protease activity expressed in human cells.
    Hamill P; Jean F
    Biochemistry; 2005 May; 44(17):6586-96. PubMed ID: 15850392
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.